Abstract
The biomedical intervention that has had a major impact on the natural history of HIV and on the global HIV epidemic is antiretroviral therapy (ART). However, the emergence of drug-resistant HIV, an inevitable consequence of increasing use of antiretroviral drugs, poses a major threat to ART success. At the turn of this century, access to life-saving ART was accelerated in low and middle-income countries with the Millennium Development Goal of 15 million individuals receiving ART by 2015 expected to be achieved. However, ART access needs to continue to expand to help bring HIV under control by 2030. The standard of care for people living with HIV in resource- limited settings differs dramatically compared to high-income countries, and not unexpectedly, ART rollout in these settings has resulted in an increase in acquired and transmitted drug resistance. Also of concern, the same drug classes used for ART have been approved or are being progressed for HIV prevention and drug resistance could mitigate their effectiveness for treatment and prevention. In the absence of an effective HIV vaccine and cure, it is imperative that the antiretroviral drug pipeline contains new classes of HIV inhibitors that are active against circulating drug-resistant strains. Studies to advance our fundamental understanding of HIV replication needs to continue, including the interplay between virus and host cell factors, to identify and characterize new drug targets for chemotherapeutic intervention.
Keywords: Antiretroviral therapy, Drug discovery, Drug resistance, HIV, Host cell factors, Pre-exposure prophylaxis.
Current Topics in Medicinal Chemistry
Title:Why Do We Need New Drug Classes for HIV Treatment and Prevention?
Volume: 16 Issue: 12
Author(s): Abdul A. Waheed and Gilda Tachedjian
Affiliation:
Keywords: Antiretroviral therapy, Drug discovery, Drug resistance, HIV, Host cell factors, Pre-exposure prophylaxis.
Abstract: The biomedical intervention that has had a major impact on the natural history of HIV and on the global HIV epidemic is antiretroviral therapy (ART). However, the emergence of drug-resistant HIV, an inevitable consequence of increasing use of antiretroviral drugs, poses a major threat to ART success. At the turn of this century, access to life-saving ART was accelerated in low and middle-income countries with the Millennium Development Goal of 15 million individuals receiving ART by 2015 expected to be achieved. However, ART access needs to continue to expand to help bring HIV under control by 2030. The standard of care for people living with HIV in resource- limited settings differs dramatically compared to high-income countries, and not unexpectedly, ART rollout in these settings has resulted in an increase in acquired and transmitted drug resistance. Also of concern, the same drug classes used for ART have been approved or are being progressed for HIV prevention and drug resistance could mitigate their effectiveness for treatment and prevention. In the absence of an effective HIV vaccine and cure, it is imperative that the antiretroviral drug pipeline contains new classes of HIV inhibitors that are active against circulating drug-resistant strains. Studies to advance our fundamental understanding of HIV replication needs to continue, including the interplay between virus and host cell factors, to identify and characterize new drug targets for chemotherapeutic intervention.
Export Options
About this article
Cite this article as:
Waheed A. Abdul and Tachedjian Gilda, Why Do We Need New Drug Classes for HIV Treatment and Prevention?, Current Topics in Medicinal Chemistry 2016; 16 (12) . https://dx.doi.org/10.2174/1568026616999151013124606
DOI https://dx.doi.org/10.2174/1568026616999151013124606 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
Addressing the Most Common Causes of Death with Niacin/NAD and Inositol Polyphosphates
The most common causes of death in the world are cardiovascular disease (CVD) and cancer. These are perhaps best addressed by reducing lipodystrophy and blockages with niacin and inositol polyphosphates (e.g., IP6+inositol) respectively when addressing CVD. Niacin serves as a vitamin by virtue of its role as a skeletal precursor ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences
Current Neuropharmacology Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets Regulation of MAPK Signaling Pathways Through Immunophilin-ligand Complex
Current Topics in Medicinal Chemistry The Implications of Iodine and its Supplementation During Pregnancy in Fetal Brain Development
Current Clinical Pharmacology Host-Pathogen Interactions Made Transparent with the Zebrafish Model
Current Drug Targets Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease
Current Neuropharmacology A Pulmonary Perspective on GASPIDs: Granule-Associated Serine Peptidases of Immune Defense
Current Respiratory Medicine Reviews Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?
Current Diabetes Reviews Modeling Follicle Stimulating Hormone Levels in Serum for Controlled Ovarian Hyperstimulation III: Improved Gonadotropin Administration
Current Pharmaceutical Biotechnology Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer’s Disease
Current Medicinal Chemistry Complications of Muscle Hematomas in Hemophilia
Cardiovascular & Hematological Disorders-Drug Targets The Urokinase Receptor Interactome
Current Pharmaceutical Design The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection
Current Pharmaceutical Design Raman Spectroscopy-based Metabonomics of HIV-infected Sera Detects Amino Acid and Glutathione Changes
Current Metabolomics The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
Current Pharmaceutical Design Biocomputational Resources Useful For Drug Discovery Against Compartmentalized Targets
Current Pharmaceutical Design